Literature DB >> 29632076

The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from Mycobacterium tuberculosis.

Katharina Weinhäupl1, Martha Brennich2, Uli Kazmaier3, Joel Lelievre4, Lluis Ballell4, Alfred Goldberg5, Paul Schanda6, Hugo Fraga7,5,8.   

Abstract

Mycobacterium tuberculosis can remain dormant in the host, an ability that explains the failure of many current tuberculosis treatments. Recently, the natural products cyclomarin, ecumicin, and lassomycin have been shown to efficiently kill Mycobacterium tuberculosis persisters. Their target is the N-terminal domain of the hexameric AAA+ ATPase ClpC1, which recognizes, unfolds, and translocates protein substrates, such as proteins containing phosphorylated arginine residues, to the ClpP1P2 protease for degradation. Surprisingly, these antibiotics do not inhibit ClpC1 ATPase activity, and how they cause cell death is still unclear. Here, using NMR and small-angle X-ray scattering, we demonstrate that arginine-phosphate binding to the ClpC1 N-terminal domain induces millisecond dynamics. We show that these dynamics are caused by conformational changes and do not result from unfolding or oligomerization of this domain. Cyclomarin binding to this domain specifically blocked these N-terminal dynamics. On the basis of these results, we propose a mechanism of action involving cyclomarin-induced restriction of ClpC1 dynamics, which modulates the chaperone enzymatic activity leading eventually to cell death.
© 2018 Weinhäupl et al.

Entities:  

Keywords:  Mycobacterium tuberculosis; antibiotic action; antibiotic resistance; chaperone; natural product; nuclear magnetic resonance (NMR); protease; small-angle X-ray scattering (SAXS)

Mesh:

Substances:

Year:  2018        PMID: 29632076      PMCID: PMC5986217          DOI: 10.1074/jbc.RA118.002251

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2.

Authors:  Ekaterina Gavrish; Clarissa S Sit; Shugeng Cao; Olga Kandror; Amy Spoering; Aaron Peoples; Losee Ling; Ashley Fetterman; Dallas Hughes; Anthony Bissell; Heather Torrey; Tatos Akopian; Andreas Mueller; Slava Epstein; Alfred Goldberg; Jon Clardy; Kim Lewis
Journal:  Chem Biol       Date:  2014-03-27

2.  Adaptor protein controlled oligomerization activates the AAA+ protein ClpC.

Authors:  Janine Kirstein; Tilman Schlothauer; David A Dougan; Hauke Lilie; Gilbert Tischendorf; Axel Mogk; Bernd Bukau; Kürşad Turgay
Journal:  EMBO J       Date:  2006-03-09       Impact factor: 11.598

Review 3.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

Review 4.  Mechanisms of Pyrazinamide Action and Resistance.

Authors:  Ying Zhang; Wanliang Shi; Wenhong Zhang; Denis Mitchison
Journal:  Microbiol Spectr       Date:  2014-08

5.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

6.  The tyrosine kinase McsB is a regulated adaptor protein for ClpCP.

Authors:  Janine Kirstein; David A Dougan; Ulf Gerth; Michael Hecker; Kürşad Turgay
Journal:  EMBO J       Date:  2007-03-22       Impact factor: 11.598

7.  Mycobacterium tuberculosis ClpC1: characterization and role of the N-terminal domain in its function.

Authors:  Narayani P Kar; Deepa Sikriwal; Parthasarathi Rath; Rakesh K Choudhary; Janendra K Batra
Journal:  FEBS J       Date:  2008-11-04       Impact factor: 5.542

8.  A molecular mechanism of chaperone-client recognition.

Authors:  Lichun He; Timothy Sharpe; Adam Mazur; Sebastian Hiller
Journal:  Sci Adv       Date:  2016-11-16       Impact factor: 14.136

9.  Modelling proteins' hidden conformations to predict antibiotic resistance.

Authors:  Kathryn M Hart; Chris M W Ho; Supratik Dutta; Michael L Gross; Gregory R Bowman
Journal:  Nat Commun       Date:  2016-10-06       Impact factor: 14.919

10.  A Dynamic molecular basis for malfunction in disease mutants of p97/VCP.

Authors:  Anne K Schuetz; Lewis E Kay
Journal:  Elife       Date:  2016-11-09       Impact factor: 8.140

View more
  8 in total

1.  Could confounding the allosteric communication of biotic machinery be an alternative path to antibiotics?

Authors:  R Andrew Byrd
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-20       Impact factor: 11.205

2.  An allosteric switch regulates Mycobacterium tuberculosis ClpP1P2 protease function as established by cryo-EM and methyl-TROSY NMR.

Authors:  Siavash Vahidi; Zev A Ripstein; Jordan B Juravsky; Enrico Rennella; Alfred L Goldberg; Anthony K Mittermaier; John L Rubinstein; Lewis E Kay
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

3.  High-Resolution Structure of ClpC1-Rufomycin and Ligand Binding Studies Provide a Framework to Design and Optimize Anti-Tuberculosis Leads.

Authors:  Nina M Wolf; Hyun Lee; Mary P Choules; Guido F Pauli; Rasika Phansalkar; Jeffrey R Anderson; Wei Gao; Jinhong Ren; Bernard D Santarsiero; Hanki Lee; Jinhua Cheng; Ying-Yu Jin; Ngoc Anh Ho; Nguyen Minh Duc; Joo-Won Suh; Celerino Abad-Zapatero; Sanghyun Cho
Journal:  ACS Infect Dis       Date:  2019-05-03       Impact factor: 5.084

Review 4.  Using chemical inhibitors to probe AAA protein conformational dynamics and cellular functions.

Authors:  Jonathan B Steinman; Tarun M Kapoor
Journal:  Curr Opin Chem Biol       Date:  2019-03-23       Impact factor: 8.822

5.  Mechanism of the allosteric activation of the ClpP protease machinery by substrates and active-site inhibitors.

Authors:  Jan Felix; Katharina Weinhäupl; Christophe Chipot; François Dehez; Audrey Hessel; Diego F Gauto; Cecile Morlot; Olga Abian; Irina Gutsche; Adrian Velazquez-Campoy; Paul Schanda; Hugo Fraga
Journal:  Sci Adv       Date:  2019-09-04       Impact factor: 14.136

6.  Marine Sediment Recovered Salinispora sp. Inhibits the Growth of Emerging Bacterial Pathogens and other Multi-Drug-Resistant Bacteria.

Authors:  Luis Contreras-Castro; Sergio MartÍnez-GarcÍa; Juan C Cancino-Diaz; Luis A Maldonado; Claudia J HernÁndez-Guerrero; Sergio F MartÍnez-DÍaz; BÁrbara GonzÁlez-Acosta; Erika T Quintana
Journal:  Pol J Microbiol       Date:  2020-09-08

Review 7.  Recent Developments on the Synthesis and Bioactivity of Ilamycins/Rufomycins and Cyclomarins, Marine Cyclopeptides That Demonstrate Anti-Malaria and Anti-Tuberculosis Activity.

Authors:  Uli Kazmaier; Lukas Junk
Journal:  Mar Drugs       Date:  2021-08-03       Impact factor: 5.118

8.  BacPROTACs mediate targeted protein degradation in bacteria.

Authors:  Francesca E Morreale; Stefan Kleine; Julia Leodolter; Sabryna Junker; David M Hoi; Stepan Ovchinnikov; Anastasia Okun; Juliane Kley; Robert Kurzbauer; Lukas Junk; Somraj Guha; David Podlesainski; Uli Kazmaier; Guido Boehmelt; Harald Weinstabl; Klaus Rumpel; Volker M Schmiedel; Markus Hartl; David Haselbach; Anton Meinhart; Markus Kaiser; Tim Clausen
Journal:  Cell       Date:  2022-06-03       Impact factor: 66.850

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.